 Peptic Ulcer Drugs Market Insights, Competitive Landscape, and Market Forecast - 2033
The global peptic ulcer drugs market continues to demonstrate stable expansion as the burden of gastrointestinal disorders remains significant worldwide. Peptic ulcers, encompassing both gastric an... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global peptic ulcer drugs market continues to demonstrate stable expansion as the burden of gastrointestinal disorders remains significant worldwide. Peptic ulcers, encompassing both gastric and duodenal ulcers, are primarily caused by Helicobacter pylori infections, excessive use of nonsteroidal anti-inflammatory drugs (NSAIDs), and lifestyle-related factors such as stress and unhealthy dietary habits. With rising awareness regarding digestive health and the availability of advanced treatment options, the demand for effective ulcer therapies is steadily increasing. Pharmaceutical companies are focusing on improving drug efficacy and safety, thereby strengthening the market outlook over the coming years.Market Insights The peptic ulcer drugs market is anticipated to reach USD 37.4 billion in 2026 and is projected to grow to USD 47.4 billion by 2033, expanding at a CAGR of 3.40% during the forecast period. The market reflects a balanced mix of established therapies and gradual innovation. Proton pump inhibitors (PPIs) continue to dominate due to their strong acid suppression capabilities and widespread clinical acceptance. Meanwhile, H2 antagonists and antibiotic therapies remain integral for comprehensive ulcer management, particularly in addressing bacterial infections and preventing recurrence. Market Drivers The increasing prevalence of gastrointestinal diseases is a major factor driving the growth of the peptic ulcer drugs market. Rising consumption of NSAIDs, growing stress levels, and changes in dietary patterns are contributing to a higher incidence of ulcers globally. In addition, the expanding geriatric population is more prone to digestive disorders, further fueling demand for effective therapeutic solutions. Improved awareness about early diagnosis and treatment is another significant driver. Access to better diagnostic tools and healthcare services has led to timely identification of peptic ulcers, thereby increasing treatment adoption. Furthermore, advancements in drug formulations, including combination therapies and improved dosing regimens, are enhancing patient outcomes and boosting market growth. Business Opportunity The market offers substantial opportunities for growth, particularly through the development of innovative therapies targeting the root causes of ulcers. Research focused on improving Helicobacter pylori eradication rates and reducing drug resistance is expected to create new avenues for pharmaceutical companies. Additionally, the growing emphasis on personalized treatment approaches is likely to influence future drug development strategies. Emerging economies present considerable potential due to expanding healthcare infrastructure and rising awareness about gastrointestinal health. Countries in Asia Pacific, Latin America, and the Middle East & Africa are witnessing increased healthcare investments and improved access to medications, making them attractive markets for expansion. The rapid growth of online pharmacies is also opening new distribution channels. Digital platforms are enhancing accessibility and convenience for patients, especially in underserved regions, thereby supporting market penetration and revenue growth. Region Analysis North America remains a leading region in the peptic ulcer drugs market, supported by advanced healthcare systems, high healthcare spending, and strong presence of key pharmaceutical companies. Early diagnosis and widespread awareness contribute to consistent demand in this region. Europe also holds a significant market share, driven by a well-established healthcare infrastructure and increasing focus on preventive healthcare. Government initiatives aimed at improving patient outcomes further support market growth. Asia Pacific is expected to register the fastest growth during the forecast period. The region benefits from a large population base, rising incidence of Helicobacter pylori infections, and increasing healthcare expenditure. Rapid urbanization and lifestyle changes are also contributing to higher prevalence of digestive disorders in countries such as China and India. Latin America and the Middle East & Africa are gradually emerging as promising markets. Improvements in healthcare access, growing awareness, and increasing availability of pharmaceutical products are driving steady growth in these regions. Key Players The competitive landscape of the peptic ulcer drugs market is characterized by the presence of several global and regional pharmaceutical companies. These players are focusing on innovation, product development, and strategic collaborations to strengthen their market positions. • AstraZeneca plc • Pfizer Inc. • Novartis AG • Takeda Pharmaceutical Company Limited • Abbott Laboratories • GlaxoSmithKline plc • Sanofi • Boehringer Ingelheim GmbH • Eisai Co., Ltd. • Daewoong Pharmaceutical Co., Ltd. • Yuhan Corporation • Zydus Lifesciences Ltd. • Sun Pharmaceutical Industries Ltd. • Dr. Reddy's Laboratories Ltd. • Teva Pharmaceutical Industries Ltd. Conclusion The peptic ulcer drugs market is expected to maintain steady growth, supported by increasing disease prevalence and continuous advancements in treatment options. While developed regions continue to dominate, emerging markets are set to play a crucial role in future expansion. Companies that prioritize innovation, affordability, and accessibility will be well-positioned to capitalize on evolving market opportunities. Market Segmentation By Drug Type • Proton Pump Inhibitors • H2 Antagonists • Antibiotics • Others By Ulcer Type • Gastric Ulcer • Duodenal Ulcer By End User • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies By Geography • North America • Europe • Asia Pacific • Latin America • Middle East & Africa Table of Contents1. Executive Summary1.1. Global Peptic Ulcer Drugs Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2026 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. COVID-19 Impact Analysis 2.5. Porter's Five Forces Analysis 2.6. Impact of Russia-Ukraine Conflict 2.7. PESTLE Analysis 2.8. Regulatory Analysis 2.9. Price Trend Analysis 2.9.1. Current Prices and Future Projections, 2025-2033 2.9.2. Price Impact Factors 3. Global Peptic Ulcer Drugs Market Outlook, 2020 - 2033 3.1. Global Peptic Ulcer Drugs Market Outlook, by Drug Type, Value (US$ Bn), 2020-2033 3.1.1. Proton Pump Inhibitors 3.1.2. H2 Antagonists 3.1.3. Antibiotics 3.1.4. Others 3.2. Global Peptic Ulcer Drugs Market Outlook, by Ulcer Type, Value (US$ Bn), 2020-2033 3.2.1. Gastric Ulcer 3.2.2. Duodenal Ulcer 3.3. Global Peptic Ulcer Drugs Market Outlook, by End User, Value (US$ Bn), 2020-2033 3.3.1. Hospital Pharmacies 3.3.2. Retail Pharmacies 3.3.3. Online Pharmacies 3.4. Global Peptic Ulcer Drugs Market Outlook, by Region, Value (US$ Bn), 2020-2033 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Latin America 3.4.5. Middle East & Africa 4. North America Peptic Ulcer Drugs Market Outlook, 2020 - 2033 4.1. North America Peptic Ulcer Drugs Market Outlook, by Drug Type, Value (US$ Bn), 2020-2033 4.1.1. Proton Pump Inhibitors 4.1.2. H2 Antagonists 4.1.3. Antibiotics 4.1.4. Others 4.2. North America Peptic Ulcer Drugs Market Outlook, by Ulcer Type, Value (US$ Bn), 2020-2033 4.2.1. Gastric Ulcer 4.2.2. Duodenal Ulcer 4.3. North America Peptic Ulcer Drugs Market Outlook, by End User, Value (US$ Bn), 2020-2033 4.3.1. Hospital Pharmacies 4.3.2. Retail Pharmacies 4.3.3. Online Pharmacies 4.4. North America Peptic Ulcer Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033 4.4.1. U.S. Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 4.4.2. U.S. Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 4.4.3. U.S. Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 4.4.4. Canada Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 4.4.5. Canada Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 4.4.6. Canada Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 4.5. BPS Analysis/Market Attractiveness Analysis 5. Europe Peptic Ulcer Drugs Market Outlook, 2020 - 2033 5.1. Europe Peptic Ulcer Drugs Market Outlook, by Drug Type, Value (US$ Bn), 2020-2033 5.1.1. Proton Pump Inhibitors 5.1.2. H2 Antagonists 5.1.3. Antibiotics 5.1.4. Others 5.2. Europe Peptic Ulcer Drugs Market Outlook, by Ulcer Type, Value (US$ Bn), 2020-2033 5.2.1. Gastric Ulcer 5.2.2. Duodenal Ulcer 5.3. Europe Peptic Ulcer Drugs Market Outlook, by End User, Value (US$ Bn), 2020-2033 5.3.1. Hospital Pharmacies 5.3.2. Retail Pharmacies 5.3.3. Online Pharmacies 5.4. Europe Peptic Ulcer Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033 5.4.1. Germany Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 5.4.2. Germany Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 5.4.3. Germany Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 5.4.4. Italy Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 5.4.5. Italy Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 5.4.6. Italy Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 5.4.7. France Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 5.4.8. France Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 5.4.9. France Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 5.4.10. U.K. Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 5.4.11. U.K. Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 5.4.12. U.K. Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 5.4.13. Spain Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 5.4.14. Spain Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 5.4.15. Spain Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 5.4.16. Russia Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 5.4.17. Russia Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 5.4.18. Russia Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 5.4.19. Rest of Europe Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 5.4.20. Rest of Europe Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 5.4.21. Rest of Europe Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 5.5. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Peptic Ulcer Drugs Market Outlook, 2020 - 2033 6.1. Asia Pacific Peptic Ulcer Drugs Market Outlook, by Drug Type, Value (US$ Bn), 2020-2033 6.1.1. Proton Pump Inhibitors 6.1.2. H2 Antagonists 6.1.3. Antibiotics 6.1.4. Others 6.2. Asia Pacific Peptic Ulcer Drugs Market Outlook, by Ulcer Type, Value (US$ Bn), 2020-2033 6.2.1. Gastric Ulcer 6.2.2. Duodenal Ulcer 6.3. Asia Pacific Peptic Ulcer Drugs Market Outlook, by End User, Value (US$ Bn), 2020-2033 6.3.1. Hospital Pharmacies 6.3.2. Retail Pharmacies 6.3.3. Online Pharmacies 6.4. Asia Pacific Peptic Ulcer Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033 6.4.1. China Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 6.4.2. China Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 6.4.3. China Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 6.4.4. Japan Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 6.4.5. Japan Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 6.4.6. Japan Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 6.4.7. South Korea Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 6.4.8. South Korea Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 6.4.9. South Korea Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 6.4.10. India Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 6.4.11. India Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 6.4.12. India Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 6.4.13. Southeast Asia Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 6.4.14. Southeast Asia Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 6.4.15. Southeast Asia Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 6.4.16. Rest of SAO Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 6.4.17. Rest of SAO Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 6.4.18. Rest of SAO Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 6.5. BPS Analysis/Market Attractiveness Analysis 7. Latin America Peptic Ulcer Drugs Market Outlook, 2020 - 2033 7.1. Latin America Peptic Ulcer Drugs Market Outlook, by Drug Type, Value (US$ Bn), 2020-2033 7.1.1. Proton Pump Inhibitors 7.1.2. H2 Antagonists 7.1.3. Antibiotics 7.1.4. Others 7.2. Latin America Peptic Ulcer Drugs Market Outlook, by Ulcer Type, Value (US$ Bn), 2020-2033 7.2.1. Gastric Ulcer 7.2.2. Duodenal Ulcer 7.3. Latin America Peptic Ulcer Drugs Market Outlook, by End User, Value (US$ Bn), 2020-2033 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies 7.3.3. Online Pharmacies 7.4. Latin America Peptic Ulcer Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033 7.4.1. Brazil Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 7.4.2. Brazil Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 7.4.3. Brazil Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 7.4.4. Mexico Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 7.4.5. Mexico Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 7.4.6. Mexico Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 7.4.7. Argentina Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 7.4.8. Argentina Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 7.4.9. Argentina Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 7.4.10. Rest of LATAM Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 7.4.11. Rest of LATAM Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 7.4.12. Rest of LATAM Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 7.5. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Peptic Ulcer Drugs Market Outlook, 2020 - 2033 8.1. Middle East & Africa Peptic Ulcer Drugs Market Outlook, by Drug Type, Value (US$ Bn), 2020-2033 8.1.1. Proton Pump Inhibitors 8.1.2. H2 Antagonists 8.1.3. Antibiotics 8.1.4. Others 8.2. Middle East & Africa Peptic Ulcer Drugs Market Outlook, by Ulcer Type, Value (US$ Bn), 2020-2033 8.2.1. Gastric Ulcer 8.2.2. Duodenal Ulcer 8.3. Middle East & Africa Peptic Ulcer Drugs Market Outlook, by End User, Value (US$ Bn), 2020-2033 8.3.1. Hospital Pharmacies 8.3.2. Retail Pharmacies 8.3.3. Online Pharmacies 8.4. Middle East & Africa Peptic Ulcer Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033 8.4.1. GCC Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 8.4.2. GCC Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 8.4.3. GCC Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 8.4.4. South Africa Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 8.4.5. South Africa Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 8.4.6. South Africa Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 8.4.7. Egypt Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 8.4.8. Egypt Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 8.4.9. Egypt Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 8.4.10. Nigeria Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 8.4.11. Nigeria Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 8.4.12. Nigeria Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 8.4.13. Rest of Middle East Peptic Ulcer Drugs Market Outlook, by Drug Type, 2020-2033 8.4.14. Rest of Middle East Peptic Ulcer Drugs Market Outlook, by Ulcer Type, 2020-2033 8.4.15. Rest of Middle East Peptic Ulcer Drugs Market Outlook, by End User, 2020-2033 8.5. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Company Vs Segment Heatmap 9.2. Company Market Share Analysis, 2025 9.3. Competitive Dashboard 9.4. Company Profiles 9.4.1. AstraZeneca plc 9.4.1.1. Company Overview 9.4.1.2. Product Portfolio 9.4.1.3. Financial Overview 9.4.1.4. Business Strategies and Developments 9.4.2. Pfizer Inc. 9.4.3. Novartis AG 9.4.4. Takeda Pharmaceutical Company Limited 9.4.5. Abbott Laboratories 9.4.6. GlaxoSmithKline plc 9.4.7. Sanofi 9.4.8. Boehringer Ingelheim GmbH 9.4.9. Eisai Co., Ltd. 9.4.10. Daewoong Pharmaceutical Co., Ltd. 9.4.11. Yuhan Corporation 9.4.12. Zydus Lifesciences Ltd. 9.4.13. Sun Pharmaceutical Industries Ltd. 9.4.14. Dr. Reddy's Laboratories Ltd. 9.4.15. Teva Pharmaceutical Industries Ltd. 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（環境・エネルギー）の最新刊レポート
Fairfield Market Research社の エネルギー・天然資源分野 での最新刊レポート
本レポートと同じKEY WORD（landscape）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
